Cargando…
The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
Less than 5% of patients with polycythemia vera (PV) show JAK2 exon 12 mutations. Although PV patients with JAK2 exon 12 mutations are known to develop post-PV myelofibrosis (MF) as well as PV with JAK2V617F, the role of JAK inhibitors in post-PV MF patients with JAK2 exon 12 mutations remains unkno...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519475/ https://www.ncbi.nlm.nih.gov/pubmed/28674362 http://dx.doi.org/10.2169/internalmedicine.56.7871 |
_version_ | 1783251622019727360 |
---|---|
author | Ikeda, Kazuhiko Ueda, Koki Sano, Takahiro Ogawa, Kazuei Ikezoe, Takayuki Hashimoto, Yuko Morishita, Soji Komatsu, Norio Ohto, Hitoshi Takeishi, Yasuchika |
author_facet | Ikeda, Kazuhiko Ueda, Koki Sano, Takahiro Ogawa, Kazuei Ikezoe, Takayuki Hashimoto, Yuko Morishita, Soji Komatsu, Norio Ohto, Hitoshi Takeishi, Yasuchika |
author_sort | Ikeda, Kazuhiko |
collection | PubMed |
description | Less than 5% of patients with polycythemia vera (PV) show JAK2 exon 12 mutations. Although PV patients with JAK2 exon 12 mutations are known to develop post-PV myelofibrosis (MF) as well as PV with JAK2V617F, the role of JAK inhibitors in post-PV MF patients with JAK2 exon 12 mutations remains unknown. We describe how treatment with a JAK1/2 inhibitor, ruxolitinib, led to the rapid amelioration of marrow fibrosis, erythrocytosis and thrombocytopenia in a 77-year-old man with post-PV MF who carried a JAK2 exon 12 mutation (JAK2H538QK539L). This case suggests that ruxolitinib is a treatment option for post-PV MF in patients with thrombocytopenia or JAK2 exon 12 mutations. |
format | Online Article Text |
id | pubmed-5519475 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | The Japanese Society of Internal Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-55194752017-07-27 The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation Ikeda, Kazuhiko Ueda, Koki Sano, Takahiro Ogawa, Kazuei Ikezoe, Takayuki Hashimoto, Yuko Morishita, Soji Komatsu, Norio Ohto, Hitoshi Takeishi, Yasuchika Intern Med Case Report Less than 5% of patients with polycythemia vera (PV) show JAK2 exon 12 mutations. Although PV patients with JAK2 exon 12 mutations are known to develop post-PV myelofibrosis (MF) as well as PV with JAK2V617F, the role of JAK inhibitors in post-PV MF patients with JAK2 exon 12 mutations remains unknown. We describe how treatment with a JAK1/2 inhibitor, ruxolitinib, led to the rapid amelioration of marrow fibrosis, erythrocytosis and thrombocytopenia in a 77-year-old man with post-PV MF who carried a JAK2 exon 12 mutation (JAK2H538QK539L). This case suggests that ruxolitinib is a treatment option for post-PV MF in patients with thrombocytopenia or JAK2 exon 12 mutations. The Japanese Society of Internal Medicine 2017-07-01 /pmc/articles/PMC5519475/ /pubmed/28674362 http://dx.doi.org/10.2169/internalmedicine.56.7871 Text en Copyright © 2017 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Case Report Ikeda, Kazuhiko Ueda, Koki Sano, Takahiro Ogawa, Kazuei Ikezoe, Takayuki Hashimoto, Yuko Morishita, Soji Komatsu, Norio Ohto, Hitoshi Takeishi, Yasuchika The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation |
title | The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation |
title_full | The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation |
title_fullStr | The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation |
title_full_unstemmed | The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation |
title_short | The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation |
title_sort | amelioration of myelofibrosis with thrombocytopenia by a jak1/2 inhibitor, ruxolitinib, in a post-polycythemia vera myelofibrosis patient with a jak2 exon 12 mutation |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519475/ https://www.ncbi.nlm.nih.gov/pubmed/28674362 http://dx.doi.org/10.2169/internalmedicine.56.7871 |
work_keys_str_mv | AT ikedakazuhiko theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT uedakoki theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT sanotakahiro theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT ogawakazuei theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT ikezoetakayuki theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT hashimotoyuko theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT morishitasoji theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT komatsunorio theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT ohtohitoshi theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT takeishiyasuchika theameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT ikedakazuhiko ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT uedakoki ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT sanotakahiro ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT ogawakazuei ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT ikezoetakayuki ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT hashimotoyuko ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT morishitasoji ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT komatsunorio ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT ohtohitoshi ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation AT takeishiyasuchika ameliorationofmyelofibrosiswiththrombocytopeniabyajak12inhibitorruxolitinibinapostpolycythemiaveramyelofibrosispatientwithajak2exon12mutation |